Keyword: Regeneron

Markets & Companies

Navigating Uncertainty in the Biopharma Market

17.05.2023 -

Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some...


Regeneron Boosts Oncology Pipeline with Checkmate Buy

22.04.2022 -

US biotech Regeneron is buying compatriot clinical-stage biopharma Checkmate Pharmaceuticals for a total equity value of about $250 million. The acquisition, expected to...


Regeneron and AstraZeneca in Obesity Partnership

30.07.2021 -

US biotech Regeneron is collaborating with AstraZeneca to research, develop and commercialize small molecule medicines targeting GPR75 for treating obesity.


Calixar Grants Regeneron Exclusive License

02.05.2019 - French biotech Calixar has signed an exclusive licensing agreement with Regeneron Pharmaceuticals, granting the US company exclusive rights to its technology and expertise to...


Sanofi Pays to Exit Regeneron Pact

10.01.2019 - France’s Sanofi is paying $462 million to exit the immuno-oncology pact it established with US biotech Regeneron in 2015 half a year earlier than planned. With the severance...


Regeneron and Bluebird Bio in Cancer Therapy Pact

09.08.2018 - US biotech companies Regeneron and bluebird bio are collaborating and applying their respective technology platforms to discover, develop and commercialize novel immune cell...


GSK and Regeneron Back UK Biobank Project

29.03.2017 - UK drugmaker GlaxoSmithKline (GSK) and US biotech Regeneron Pharmaceuticals are investing in a gene sequencing project that uses anonymous patient data held by the UK Biobank. The...


Sanofi and Regeneron Appeal Praluent Sales Halt

11.01.2017 - French drugmaker Sanofi and US marketing partner Regeneron have announced they will appeal a ruling by a US federal district court judge that would prevent them from selling their...